Gilead Sciences GILD NASDAQ:GILD

Biotech GAiners: BioCryst Pharmaceuticals (NASDAQ:BCRX), Dyax Corp. (NASDAQ:DYAX), Novavax, Inc. (NASDAQ:NVAX), Merrimack Pharmaceuticals Inc (NASDAQ:MACK)

BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) shares closed up nearly 11% on Tuesday after the company reported positive data from its OPuS-1 mid-stage study involving BCX4161 as a treatment for hereditary angioedema, or HAE. This is a rare immune disorder that can cause swelling of the face, breathing airways, and also causes abdominal cramping. According to the preliminary results from the company’s proof-of-concept study, BCX4161 met both … Continue reading Biotech GAiners: BioCryst Pharmaceuticals (NASDAQ:BCRX), Dyax Corp. (NASDAQ:DYAX), Novavax, Inc. (NASDAQ:NVAX), Merrimack Pharmaceuticals Inc (NASDAQ:MACK)

Biotech Most Volatile: Celldex Therapeutics (NASDAQ:CLDX), Dyax Corp. (NASDAQ:DYAX), Insmed Incorporated (NASDAQ:INSM), Novavax (NASDAQ:NVAX)

Celldex Therapeutics Inc. (NASDAQ:CLDX) options contracts experienced a new 90-day record for call contracts where a total of 5,803 call contracts were traded in the busy trading session. The contract spread yielded a 0.58 put/call ratio where 1.7 call contracts were traded for each put contract. Celldex Therapeutics, Inc. (NASDAQ:CLDX) stock performance was 0.07% in last session and finished the day at $13.73. Traded volume … Continue reading Biotech Most Volatile: Celldex Therapeutics (NASDAQ:CLDX), Dyax Corp. (NASDAQ:DYAX), Insmed Incorporated (NASDAQ:INSM), Novavax (NASDAQ:NVAX)

Health Stocks In New: Amgen (NASDAQ:AMGN), Novavax (NASDAQ:NVAX), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD)

Amgen Inc. (NASDAQ:AMGN) carries a Zacks Rank #1 (Strong Buy). Amgen, Inc. (NASDAQ:AMGN) stock performance was -1.90% in last session and finished the day at $111.94. Traded volume was 7.26million shares in the last session and the average volume of the stock remained 3.63million shares. The beta of the stock remained 0.51. Amgen, Inc. (NASDAQ:AMGN) insider ownership is 0.10%. Novavax, Inc. (NASDAQ:NVAX), a clinical-stage biopharmaceutical … Continue reading Health Stocks In New: Amgen (NASDAQ:AMGN), Novavax (NASDAQ:NVAX), Ariad Pharmaceuticals (NASDAQ:ARIA), MannKind Corporation (NASDAQ:MNKD)

FB Nasdaq FB Facebook

Biotech Gainers: Novavax (NASDAQ:NVAX), OXiGENE Inc (NASDAQ:OXGN), Imprimis Pharmaceuticals (NASDAQ:IMMY), Oramed Pharmaceuticals (NASDAQ:ORMP)

Novavax (NASDAQ:NVAX) Director Richard Douglas acquired 50,000 shares of Novavax stock in a transaction that occurred on Tuesday, March 25th. Novavax, Inc. (NASDAQ:NVAX) stock performance was 8.47% in last session and finished the day at $4.48. Traded volume was 7,425,052 million shares in the last session and the average volume of the stock remained 5.05 million shares. The beta of the stock remained 2.15. Novavax, … Continue reading Biotech Gainers: Novavax (NASDAQ:NVAX), OXiGENE Inc (NASDAQ:OXGN), Imprimis Pharmaceuticals (NASDAQ:IMMY), Oramed Pharmaceuticals (NASDAQ:ORMP)

Biotech Active Stocks: Arrowhead Research (NASDAQ:ARWR), Gilead Sciences (NASDAQ:GILD), Novavax (NASDAQ:NVAX), MannKind Corporation (NASDAQ:MNKD)

Arrowhead Research Corp (NASDAQ:ARWR) stock had its “buy” rating reaffirmed by stock analysts at Deutsche Bank in a report issued on Monday, American Banking News.com reports. Arrowhead Research Corp (NASDAQ:ARWR) stock performance was -16.09% in last session and finished the day at $17.37. Traded volume was 7.56million shares in the last session and the average volume of the stock remained 1.44million shares. The beta of … Continue reading Biotech Active Stocks: Arrowhead Research (NASDAQ:ARWR), Gilead Sciences (NASDAQ:GILD), Novavax (NASDAQ:NVAX), MannKind Corporation (NASDAQ:MNKD)

Biotech Losers: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Celldex Therapeutics, Inc. (NASDAQ:CLDX), Novavax, Inc. (NASDAQ:NVAX), Biogen Idec Inc (NASDAQ:BIIB)

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) and AstraZeneca (NYSE:AZN) are among those companies with late stage drugs in trials that specifically target genetic mutations. Both BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)’s BMN-673, which is in phase 3 trials, and Astra’s Olaparib, which may get the EU’s go-ahead in ovarian cancer this year, address a mutation of the BRCA 1 and BRCA 2 gene that is often associated with breast … Continue reading Biotech Losers: BioMarin Pharmaceutical Inc. (NASDAQ:BMRN), Celldex Therapeutics, Inc. (NASDAQ:CLDX), Novavax, Inc. (NASDAQ:NVAX), Biogen Idec Inc (NASDAQ:BIIB)